OSR Holdings, Inc. (NASDAQ: OSRH) has made a significant disclosure regarding its business development activities through a Form 8-K filing dated March 16, 2026. The company provided insights into its drug development subsidiary, Vaximm AG, particularly focusing on ongoing negotiations with SillaJen, Inc., a South Korean biopharmaceutical company. The discussions center around a potential licensing arrangement for Pexa-Vec, an oncolytic immunotherapy currently in Phase 2 clinical trials for treating Renal Cell Carcinoma (RCC). While the negotiations are active, OSR Holdings has clarified that no binding agreements have been reached yet, emphasizing that there is no guarantee of a successful outcome.

Additionally, OSR Holdings has revealed that preliminary discussions have taken place regarding a potential acquisition of a controlling stake in SillaJen, representing approximately 16% of its total outstanding shares. These discussions are still in the early stages, and no specific terms or agreements have been established. The company aims to ensure that all investors and the public have equal access to this information, adhering to Regulation FD requirements.

The disclosure highlights OSR Holdings' strategic approach to expanding its portfolio and enhancing its market position through potential collaborations and acquisitions. However, the company has cautioned that both the licensing negotiations and acquisition discussions are subject to further negotiations and due diligence, with no assurance of a definitive agreement being reached. OSR Holdings does not intend to provide further updates unless there are material developments that warrant public disclosure.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.